Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2007 Feb;48(2):375-8.
doi: 10.1111/j.1528-1167.2006.00931.x.

Outcome measurement after vagal nerve stimulation therapy: proposal of a new classification

Affiliations
Free article
Comparative Study

Outcome measurement after vagal nerve stimulation therapy: proposal of a new classification

John C McHugh et al. Epilepsia. 2007 Feb.
Free article

Abstract

Purpose: Vagal nerve stimulation (VNS) is an adjunctive palliative therapy for refractory epilepsy. Effects of treatment are varied and some, such as the use of an external magnet for seizure termination, are unique to VNS. No accepted standard exists for outcome measurement after VNS treatment. We present a novel classification for outcome, which includes assessment of both seizure frequency and severity in VNS-treated patients.

Methods: We devised a classification system modeled on the Engel classification for surgically treated patients, but tailored for use in VNS therapy, which incorporates five classes of outcome. We retrospectively reviewed VNS-treated patients in our centre, and used the data to illustrate our system and compare it with the Engel model.

Results: With this system, 48 patients (mean age, 30 years) were followed up over a median of 18 months. Seventy-eight percent had partial epilepsy. Sixteen and a half percent experienced class I outcome (>80% seizure-frequency reduction). Twenty percent had class II improvement (50-79% seizure-frequency reduction). One-third had no improvement (class V). The remaining patients comprised class III (seizure-frequency reduction <50%) or class IV (magnet benefit alone) outcomes. Class I-III outcomes were further subdivided according to effects on ictal or postictal severity.

Conclusions: We propose a new classification, which can be used for all epilepsies and which reflects outcome measures beyond seizure-frequency reduction alone. Use of this system would allow greater comparison between future studies of VNS therapy.

PubMed Disclaimer

Similar articles

Cited by

Publication types